-
公开(公告)号：US20210316303A1
公开(公告)日：2021-10-14
申请号：US17176561
申请日：2021-02-16
Inventor： Richard Chasen Spero , Jay Kenneth Fisher , Richard Superfine
IPC: B01L3/00 , G01N33/543
Abstract: A flow cell is provided that includes surface-attached structures in a chamber. The structures are movable in response to a magnetic or electric field. A target extraction or isolation system includes the flow cell and a driver configured for applying a magnetic or electric field to the interior of the flow cell to actuate movement of the structures. The flow cell may be utilized to extract or isolate a target from a sample flowing through the flow cell. Further, a microfluidic system is provided that includes surface-attached structures and a microarray, wherein actuated motion of the surface-attached structures is used to enhance flow, circulation, and/or mixing action for analyte capture on the microarray.
-
82.发明授权
公开(公告)号：US11123302B2
公开(公告)日：2021-09-21
申请号：US15247840
申请日：2016-08-25
Applicant: The University of North Carolina at Chapel Hill , The Arizona Board of Regents on behalf of The University of Arizona , The Regents of the University of Colorado, a body corporate
Inventor： Paul A. Dayton , Paul S. Sheeran , Terry O. Matsunaga , Mark A. Borden
Abstract: Acoustically activatable particles having low vaporization energy are disclosed. A particle of material includes a first substance that includes at least one component that has a boiling point below 25° C. at atmospheric pressure. A second substance, different from the first substance, encapsulates the first substance to create the particle. The particle has a core consisting of a liquid and is an activatable phase change agent. The second substance includes a polymeric brush layer to prevent aggregation and coalescence.
-
公开(公告)号：US20210268503A1
公开(公告)日：2021-09-02
申请号：US17260125
申请日：2019-07-15
Applicant: UNIVERSITY OF KANSAS , THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL , BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE , NORTHEASTERN UNIVERSITY , CLARKSON UNIVERSITY
Inventor： Steven A. SOPER , Collin J. MCKINNEY , Elizabeth PODLAHA-MURPHY , Sunggook PARK
IPC: B01L3/00 , C12Q1/6869 , G01N33/68
Abstract: Disclosed are nanofluidic analytical devices. The devices employ a sample processing region that includes a plurality of fluidically connected sample handling elements that, in combination, affect a physical change on a sample introduced into the sample processing region. This physical change can include, for example, purification of an analyte of interest present in the sample, concentration of an analyte of interest present in the sample, chemical modification (e.g., cleavage and/or chemical derivatization) of an analyte of interest present in the sample, or a combination thereof. The analytical devices further include a nanochannel comprising a plurality of in-plane nanopores in series fluidically coupled to the sample processing region. The in-plane nanopores can be used to detect and/or analyze analyte(s) present in the sample following processing by the sample processing region. These analytical devices can advantageously provide for the label-free detection of single molecules.
-
公开(公告)号：US20210260098A1
公开(公告)日：2021-08-26
申请号：US17254145
申请日：2019-06-19
Inventor： Jian Liu , Jine Li , Guowei Su , Rafal Pawlinski , Erica Sparkenbaugh
IPC: A61K31/737 , A61P39/02
Abstract: Chondroitin sulfate compounds comprising chondroitin sulfate backbone 19 mer, CS-A 19 mer, CS-C 19 mer, CS-E 19 mer, C8 backbone 13 mer, C8-A 13 mer, CS-C 13 mer, CS-E 13 mer and/or combinations thereof are provided. Methods of treating histone toxicity in a subject are provided, the methods including administering to a subject a chondroitin sulfate compound to treat the histone toxicity in the subject. Pharmaceutical compositions for use in treating histone toxicity and/or sepsis are provided. Methods of treating sepsis in a subject are provided, the methods including administering to a subject a chondroitin sulfate compound to treat the sepsis in the subject.
-
公开(公告)号：US20210252067A1
公开(公告)日：2021-08-19
申请号：US17251397
申请日：2019-05-24
Inventor： Gianpietro Dotti , Soldano Ferrone , Hannah Reid Hudson , Elena Dukhovlinova , Cristina Ferrone , Xinhui Wang
IPC: A61K35/17 , C07K14/725 , C07K16/30 , G01N33/50
Abstract: The present invention provides a chimeric antigen receptor (CAR) that recognizes CSPG4 as well as methods of use in the treatment of diseases and disorders.
-
公开(公告)号：US20210236621A1
公开(公告)日：2021-08-05
申请号：US17259352
申请日：2019-07-09
Applicant: Arizona Board of Regents on Behalf of The University of Arizona , The University of North Carolina at Chapel Hill , The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
Inventor： Felicia Goodrum , Nathaniel Moorman , Jeremy Kamil
Abstract: Viral promoters and compositions and methods of use thereof are provided. Compositions include viruses with impaired ability to reactivate from latency, and pharmaceutical compositions and method of use thereof. The genome of the viruses include one or more mutations that reduce expression from one or more promoters that regulate expression of viral genes during reactivation from latency. The mutation(s) are typically in a region of the viral genome that includes (i) promoter elements of the iP1 promoter of human cytomegalovirus, or the sequence of another virus corresponding thereto (e.g., an iP1 promoter homolog); (ii) promoter elements of the iP2 promoter of human cytomegalovirus, or sequence of another virus corresponding thereto (e.g., an iP2 promoter homolog); or (iii) a combination thereof. In some embodiments the virus encodes one or more heterologous antigens. The viruses can be used as vaccines to induce prophylactic and therapeutic immune responses in subjects in need thereof.
-
公开(公告)号：US11078495B2
公开(公告)日：2021-08-03
申请号：US15768438
申请日：2016-10-14
Inventor： Tal Kafri
IPC: C12N15/86 , C12N15/113
Abstract: The present invention provides an integration-defective lentiviral vector based on a parental lentivirus and related methods, the integration-defective lentiviral vector including one or more of the following: (a) a mutation, deletion or other modification of one or more binding sites for a host factor involved in gene silencing; (b) an addition of one or more binding sites for a transcription activator, which can be natural (such as but not limited to ubiquitous and/or tissue/cell type specific) including but not limited to SP1 NFkB, or synthetic including but not limited to binding sites for tetracycline regulated trans activators tTA, rtTA, tT65, and/or rtT65; (c) one or more nucleic acid sequences from a SV40 genome, wherein the one or more sequences are obtained from a region of the SV40 genome upstream to the SV40 poly-adenylation signal; (d) a shRNA expression cassette, which encodes a shRNA directed to a host gene involved in epigenetic silencing and/or in DNA repair pathways; or (e) any combination of (a), (b), (c) and (d), wherein as compared to the parental lentivirus, the integration-defective lentiviral vector resists gene silencing.
-
公开(公告)号：US20210222152A1
公开(公告)日：2021-07-22
申请号：US17054383
申请日：2019-05-10
Inventor： Samantha Gail Pattenden , Paul Alexander Dayton , Ian Jonathan Davis , Austin Louis Quimby
IPC: C12N15/10 , C12Q1/6806
Abstract: Methods of extracting chromatin from tissue, such as formalin fixed, paraffin embedded (FFPE) tissue, are provided. The methods are rapid, simple, and preserve the chromatin signature. The methods can include, for example, removal of the tissue from the paraffin, enzymatic digestion of the extracellular matrix, and exposure to ultrasound energy, optionally in the presence of a cavitation enhancement agent, such as microbubbles, nanobubbles, and/or phase-change nanodroplets. The methods can also include a mechanical tissue dissociation step. The methods provide chromatin fragments that are free of enzyme bias from fragmentation by enzymes such as micrococcal nuclease (MNase) and that are of optimal size for further quantification and/or identification. Kits for extracting chromatin from tissue are also provided.
-
公开(公告)号：US11052149B2
公开(公告)日：2021-07-06
申请号：US16334153
申请日：2017-09-19
Inventor： Jenny P.-Y. Ting , Robert Junkins , Brandon Johnson , Kristy Ainslie , Eric Bachelder , Matthew Gallovic , Michael Collier , Ning Cheng
IPC: A61K39/39 , A61K39/145 , A61P31/16 , A61P35/00 , A61P37/04 , C07K16/28 , A61K39/00 , A61K31/7084 , A61K39/12 , A61K9/127 , A61K31/4745 , A61K9/16 , A61P25/28 , A61K9/00
Abstract: The present invention provides a composition comprising a) a polyacetal polymer, a polyester polymer and/or a biodegradable polymer; b) a cyclic dinucleotide; and c) an antigen and/or an antibody, as well as methods of using same.
-
90.发明授权
公开(公告)号：US11049476B2
公开(公告)日：2021-06-29
申请号：US15522765
申请日：2015-11-04
Inventor： Henry Fuchs , Anselmo A. Lastra , John Turner Whitted , Feng Zheng , Andrei State , Gregory Welch
Abstract: Methods, systems, and computer readable media for minimal-latency tracking and display for matching real and virtual worlds in head-worn displays are disclosed. According to one aspect, a method for minimal-latency tracking and display for matching real and virtual worlds in head-worn displays includes calculating a desired image, calculating an error image as the difference between the desired image and an image currently being perceived by a user, identifying as an error portion a portion of the error image having the largest error, updating a portion of a projected image that corresponds to the error portion, and recalculating the image currently being perceived by a user based on the updated projected image.
